BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20645882)

  • 21. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
    Bydal P; Luu-The V; Labrie F; Poirier D
    Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
    Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure and function of human 17beta-hydroxysteroid dehydrogenases.
    Lukacik P; Kavanagh KL; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):61-71. PubMed ID: 16414178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
    Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
    Lin SX; Poirier D; Adamski J
    Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
    Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
    Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 17ß-hydroxysteroid dehydrogenase inhibitors.
    Day JM; Tutill HJ; Purohit A
    Minerva Endocrinol; 2010 Jun; 35(2):87-108. PubMed ID: 20595938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
    Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated view on 17beta-hydroxysteroid dehydrogenases.
    Moeller G; Adamski J
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):7-19. PubMed ID: 19027824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
    Smuc T; Rizner TL
    Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
    Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.
    Tremblay MR; Lin SX; Poirier D
    Steroids; 2001 Nov; 66(11):821-31. PubMed ID: 11576622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.